Page last updated: 2024-11-08

alanine and Cranial Nerve Diseases

alanine has been researched along with Cranial Nerve Diseases in 1 studies

Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.

Cranial Nerve Diseases: Disorders of one or more of the twelve cranial nerves. With the exception of the optic and olfactory nerves, this includes disorders of the brain stem nuclei from which the cranial nerves originate or terminate.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jacobs, M1
Rodger, A1
Bell, DJ1
Bhagani, S1
Cropley, I1
Filipe, A1
Gifford, RJ1
Hopkins, S1
Hughes, J1
Jabeen, F1
Johannessen, I1
Karageorgopoulos, D1
Lackenby, A1
Lester, R1
Liu, RS1
MacConnachie, A1
Mahungu, T1
Martin, D1
Marshall, N1
Mepham, S1
Orton, R1
Palmarini, M1
Patel, M1
Perry, C1
Peters, SE1
Porter, D1
Ritchie, D1
Ritchie, ND1
Seaton, RA1
Sreenu, VB1
Templeton, K1
Warren, S1
Wilkie, GS1
Zambon, M1
Gopal, R1
Thomson, EC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Characterizing SARS-CoV-2 Persistence in Host Reservoirs, Post-viral Sequelae, and Associations With Host and Viral Determinants in a Cohort of Convalescent COVID-19 Cases[NCT04448145]325 participants (Anticipated)Observational2020-03-26Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for alanine and Cranial Nerve Diseases

ArticleYear
Late Ebola virus relapse causing meningoencephalitis: a case report.
    Lancet (London, England), 2016, Jul-30, Volume: 388, Issue:10043

    Topics: Acute Disease; Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Cranial Nerve Diseases; Di

2016